about bpl

Bio Products Laboratory Ltd.


PRESS RELEASE: FDA Approves US Gammaplex 10%

 8 February 2017 -   FDA Approves Bio Products Laboratory's Gammaplex® 10% for Treatment of Primary immunodeficiency and Chronic Immune Thrombocytopenic Purpura Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies, today announced that the U.S. Food and Drug Administration (FDA) has ...

Date added: Wednesday 8th February 2017

Patient information leaflets